Every Form 4 that Summit Therapeutics Inc. (SMMT) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow SMMT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SMMT filings page.
Summit Therapeutics Inc. Co-CEO Mahkam Zanganeh reported a large indirect open-market purchase of 3,810,000 shares of Common Stock at $13.12 per share on behalf of her spouse. The filing also lists existing holdings, including 31,000 direct shares and substantial indirect stakes through family trusts and an immediate family member. A footnote states she disclaims beneficial ownership beyond her pecuniary interest.
Summit Therapeutics Inc. Co-Chief Executive Officer and director Robert W. Duggan reported an open-market purchase of 3,810,000 shares of common stock at $13.12 per share. After this transaction, he directly holds 573,883,879 shares of Summit Therapeutics common stock.
The filing also lists indirect holdings attributed to entities and individuals related to him, including 10,199,776 shares held by the Shaun Zanganeh Irrevocable Trust, 25,824,474 shares held by the Mahkam Zanganeh Revocable Trust, 31,000 shares held by his spouse, and 76,680 shares held by an immediate family member of his spouse. He disclaims beneficial ownership of these indirect holdings except to the extent of any pecuniary interest.
Summit Therapeutics Inc. director and Co‑CEO Robert W. Duggan reported an indirect open‑market purchase of 100,000 shares of Common Stock at $14.60 per share. The transaction was made by the Mahkam Zanganeh Revocable Trust, with his spouse as trustee, bringing that trust’s reported holdings to 25,824,474 shares.
The filing also lists additional positions associated with Duggan, including 570,073,879 shares held directly, 10,199,776 shares held by the Shaun Zanganeh Irrevocable Trust, 31,000 shares held by his spouse, and 76,680 shares held by an immediate family member of his spouse. A footnote states he disclaims beneficial ownership of these securities except to the extent of any pecuniary interest.
Summit Therapeutics Inc. Co-Chief Executive Officer Mahkam Zanganeh, acting through the Mahkam Zanganeh Revocable Trust where she serves as trustee, bought 100,000 shares of common stock in an open-market purchase at $14.60 per share.
Following this transaction, that revocable trust held 25,824,474 shares of Summit Therapeutics common stock. Additional holdings reported include 31,000 shares held directly, 10,199,776 shares held by the Shaun Zanganeh Irrevocable Trust with her as trustee, 570,073,879 shares held by her spouse, and 76,680 shares held by an immediate family member. She disclaims beneficial ownership of these securities beyond any pecuniary interest.
Summit Therapeutics Inc. director and executive officer Manmeet Singh Soni, who serves as COO and CFO, reported open-market purchases of the company’s common stock. On June 4, 2026, he bought 25,000 shares at $14.43 and another 25,000 shares at $14.46.
These transactions total 50,000 shares of Summit Therapeutics common stock acquired in the open market, leaving him with a direct ownership stake of more than three million shares.
Summit Therapeutics Inc. reported that its Chief Accounting Officer, Anand Bhaskar, received a stock option grant. On January 8, 2026, Bhaskar was awarded an option to purchase 30,000 shares of Summit Therapeutics common stock at an exercise price of $18.83 per share.
The option becomes exercisable over time, vesting in four equal annual installments, with the first installment scheduled to vest on January 8, 2027. The option expires on January 8, 2036. Following this grant, Bhaskar beneficially owns 30,000 derivative securities directly in the form of this stock option.
Summit Therapeutics Inc. director Robert F. Booth reported receiving two stock option grants on January 2, 2026. He was granted stock options to purchase 35,000 shares of common stock at an exercise price of $17.52 per share, expiring on January 2, 2036. These options vest in four quarterly installments on March 31, June 30, September 30 and December 31 of the year of grant, as long as he remains a non-salaried director on each vesting date.
Booth was also granted stock options covering 7,180 shares of common stock, also at an exercise price of $17.52 per share and expiring on January 2, 2036. These options vest in four quarterly installments on March 31, June 30, September 30 and December 31 following his election as a director and were issued under the company’s Director Retainer Option Election Plan in lieu of $62,900 in retainer fees.
Summit Therapeutics Inc. reported that director Kenneth A. Clark received new stock option awards. On January 2, 2026, he was granted 35,000 stock options with an exercise price of $17.52 per share, vesting in four quarterly installments during the year of grant, as long as he continues serving as a non-salaried director on each vesting date. On the same date, he also received a separate grant of 17,796 stock options with the same exercise price, issued under the company’s Director Retainer Option Election Plan in lieu of $155,900 of cash retainer fees. All reported options are held directly.
Summit Therapeutics Inc. reported that director Alessandra Cesano received new stock option awards. On 01/02/2026, she was granted a stock option for 35,000 shares of common stock at an exercise price of $17.52 per share, expiring on 01/02/2036. These shares vest in four quarterly installments on March 31, June 30, September 30 and December 31 of the grant year, as long as she continues serving as a non-salaried director.
She was also granted a separate stock option for 3,219 shares of common stock at the same $17.52 exercise price, expiring on 01/02/2036. This option was issued under the company’s Director Retainer Option Election Plan in lieu of cash retainer fees of $28,200 and vests in four quarterly installments on March 31, June 30, September 30 and December 31 following her election, contingent on continued board service.
Summit Therapeutics (SMMT) reported an insider transaction by director Yu Xia. On 10/21/2025, she acquired 533,617 shares of common stock at $18.74 per share in a private placement pursuant to a definitive agreement, anticipated to close on or about 10/23/2025. After the transaction, 32,057,147 shares were beneficially owned indirectly through Akeso, Inc. Dr. Xia disclaims beneficial ownership of Akeso’s holdings except to the extent of her pecuniary interest.
Summit Therapeutics (SMMT) insider transaction: Chief Accounting Officer Bhaskar Anand reported acquiring 26,680 shares of common stock at $18.74 per share on 10/21/2025. The shares were acquired in a private placement under a definitive agreement dated October 21, 2025, with the transaction anticipated to close on or about October 23, 2025.
Following the reported transaction, Anand beneficially owned 159,751 shares directly. Holdings include shares previously acquired through the company’s employee stock purchase plan.
Summit Therapeutics Inc. (SMMT) reported an insider purchase by its COO and CFO, who is also a director. On 10/21/2025, the reporting person acquired 53,361 shares of common stock at $18.74 per share, coded as an acquisition (A).
Following this transaction, the reporting person beneficially owned 3,073,603 shares, held directly. The shares were acquired in a private placement under a definitive agreement dated October 21, 2025, with the transaction anticipated to close on or about October 23, 2025.
Summit Therapeutics (SMMT) Co‑CEO, director, and 10% owner Robert W. Duggan reported acquisitions of common stock. He acquired 13,980,789 shares at $18.74 in a private placement pursuant to a definitive agreement dated October 21, 2025, anticipated to close on or about October 23, 2025. He also acquired 266,808 shares indirectly at $18.74 and purchased 26,680 shares at $18.74.
Following these transactions, he beneficially owned 570,073,879 shares directly and 25,724,474 shares indirectly via a trust, with additional indirect holdings of 76,680, 31,000, and 10,199,776 shares through family and related trusts.
Summit Therapeutics (SMMT) Co‑Chief Executive Officer and director Mahkam Zanganeh, a 10% owner, reported multiple share purchases dated 10/21/2025 tied to a private placement at $18.74 per share. Reported acquisitions include 266,808 shares by the Mahkam Zanganeh Revocable Trust, 26,680 shares for an immediate family member, and 13,980,789 shares by her spouse. The filing notes the transaction was pursuant to a definitive agreement and is anticipated to close on or about October 23, 2025. The report includes a standard disclaimer of beneficial ownership for certain indirect holdings.